Dr. Robin Downing podcast highlights multimodal OA pain care
Clinician’s Brief has published a sponsored podcast episode featuring veterinary pain specialist Dr. Robin Downing on practical management of osteoarthritis pain in companion animals, with a focus on moving beyond a single-drug mindset. The episode centers on how clinicians can build more complete pain-control plans and improve conversations with pet parents about recognizing pain, mobility changes, and quality-of-life goals. That message lands as osteoarthritis care keeps evolving, with the 2022 AAHA pain management guidelines emphasizing regular pain assessment, individualized plans, multimodal therapy, monitoring, and client education. It also aligns with related Clinician’s Brief podcast discussion from sports medicine and rehab specialist Dr. Matt Brunke, who stressed that mobility and joint health management should extend beyond medications and supplements alone and include practical support for day-to-day function in both dogs and cats, including often-overlooked feline patients with obesity-related or age-related OA. At the same time, the treatment landscape has expanded with newer options such as anti-NGF monoclonal antibodies, including Librela for dogs, which the FDA approved in May 2023. (cliniciansbrief.com)
Why it matters: For veterinary professionals, the practical takeaway is that osteoarthritis pain management is increasingly about case selection, monitoring, expectation-setting, and whole-patient mobility planning, not just choosing a product. AAHA’s guidance stresses combining pharmacologic and non-pharmacologic tools, and Brunke’s discussion reinforces that mobility itself is a major quality-of-life marker for pet owners, especially in chronic OA, obesity, ligament injury, and recovery cases. FDA and post-approval safety communications around Librela have also reinforced the need for careful follow-up, pet parent counseling, and discussion of both benefit and risk before and during treatment. FDA updated Librela’s safety labeling in February 2025 to add stronger client information and discussion points, including possible neurologic, mobility, urinary, and gastrointestinal adverse events, and advice to reassess response before each injection. (aaha.org)
What to watch: Expect continued attention on multimodal OA protocols, pet parent communication, rehabilitation and weight-management strategies that support joint health, and how clinicians integrate newer biologics as safety surveillance and expert debate continue. (frontiersin.org)